期刊
MOLECULAR THERAPY-ONCOLYTICS
卷 27, 期 -, 页码 288-304出版社
CELL PRESS
DOI: 10.1016/j.omto.2022.11.004
关键词
-
资金
- Glioblastoma Translational Center of Excellence at Abramson Cancer Center
- Sheldon G. Adelson Medical Research Foundation
- National Institutes of Health [R35NS116843, R35NS097370]
The study demonstrates that using IAP antagonist birinapant can enhance the efficacy of CAR T cell therapy for glioblastoma, effectively preventing tumor antigenic escape and increasing CAR T cell-mediated bystander death of glioblastoma cells.
Antigen heterogeneity that results in tumor antigenic escape is one of the major obstacles to successful chimeric antigen recep-tor (CAR) T cell therapies in solid tumors including glioblas-toma multiforme (GBM). To address this issue and improve the efficacy of CAR T cell therapy for GBM, we developed an approach that combines CAR T cells with inhibitor of apoptosis protein (IAP) antagonists, a new class of small mol-ecules that mediate the degradation of IAPs, to treat GBM. Here, we demonstrated that the IAP antagonist birinapant could sensitize GBM cell lines and patient-derived primary GBM organoids to apoptosis induced by CART cell-derived cy-tokines, such as tumor necrosis factor. Therefore, birinapant could enhance CAR T cell-mediated bystander death of anti-gen-negative GBM cells, thus preventing tumor antigenic escape in antigen-heterogeneous tumor models in vitro and in vivo. In addition, birinapant could promote the activation of NF -KB signaling pathways in antigen-stimulated CAR T cells, and with a birinapant-resistant tumor model we showed that birinapant had no deleterious effect on CAR T cell func-tions in vitro and in vivo. Overall, we demonstrated the poten-tial of combining the IAP antagonist birinapant with CAR T cells as a novel and feasible approach to overcoming tumor antigen heterogeneity and enhancing CAR T cell therapy for GBM.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据